Physician

Laila Hassan, M.D. P.A.

According to 2025 Medicare claims, Laila Hassan, M.D. P.A. (NPI: 1942395496) practices rheumatology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Harris, TX. This provider's primary affiliated billing organization is LAILA A. HASSAN, M.D., P.A. (NPI: 1336626126) and primary practice location at 77089-6048.

Hassan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 475 traditional Medicare patients, billed 192,893 HCPCS/CPT codes, and received $2,460,797 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,741 prescription claims across 639 beneficiaries totaling $1,261,998 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2019 DME data shows 11 claims. Open Payments data shows 95 records totaling $102,537. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $996,259 and ending at $1,261,998. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	638	90,366	$1,191,231
2016	668	131,983	$2,026,205
2017	661	159,524	$2,460,840
2018	600	156,148	$2,654,207
2019	594	167,577	$2,740,398
2020	547	168,155	$2,681,378
2021	549	165,285	$2,882,156
2022	513	196,922	$2,648,740
2023	481	192,173	$2,425,111
2024	475	192,893	$2,460,797

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	462	3,799	$996,259
2016	493	3,639	$1,187,252
2017	560	4,081	$1,512,064
2018	547	3,939	$976,104
2019	561	3,801	$1,339,814
2020	550	3,673	$2,238,128
2021	586	3,607	$1,887,240
2022	585	3,643	$1,314,804
2023	594	3,665	$1,062,030
2024	639	3,741	$1,261,998

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$3,084
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	375	906	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	175	267	$73
77080	Dxa bone density measurement of hip, pelvis, spine	254	254	$41
90661	Influenza vaccine, trivalent derived from cell cultures	142	142	$36
96372	Injection of drug or substance under skin or into muscle	158	311	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	32	1,568	$373,691
Enbrel Sureclick	Etanercept	29	812	$233,225
Rinvoq	Upadacitinib	18	780	$181,426
Tymlos	Abaloparatide	19	620	$55,142
Prolia	Denosumab	30	5,250	$50,779

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	80	$1,945	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	15	$100,592	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Laila Hassan, M.D. P.A.?

Tedicare shows public-source Medicare data for Laila Hassan, M.D. P.A. (NPI 1942395496), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Laila Hassan, M.D. P.A. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Laila Hassan, M.D. P.A.?

Laila Hassan, M.D. P.A. is linked to LAILA A. HASSAN, M.D., P.A. (billing NPI 1336626126) in the available physician profile data.

Does Laila Hassan, M.D. P.A. have Open Payments data?

Laila Hassan, M.D. P.A. has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.